Daiichi Sankyo Acquires Rights for Astellas’ Three Therapies to Boost its Presence in Asia

 Daiichi Sankyo Acquires Rights for Astellas’ Three Therapies to Boost its Presence in Asia

Daichii Sankyo Acquires Rights for Astellas’ Three Therapies to Boost its Presence in Asia

Shots:

  • Astellas to receive ~$88.3M as up front for its three products. Daiichi to get rights and obligations, including manufacturing and marketing approvals for Nasea (ramosetron), Perdipine (nicardipine) and Oldeca (barnidipine) from Dec’2019
  • The focus of the agreement is to strengthen Daiichi’s presence in Asia and to contribute to healthcare in Asia by acquiring two anti-hypertensive and anti-emetic therapies from Astellas
  • Nasea is an antiemetic therapy, expected to have synergic effect with Daiichi’s Mirogabalin and the cancer therapies while Perdipine & Oldeca are anti-hypertensive therapies, expected to be utilized in combination with Daiichi’s cardiovascular products, Olmesartan and Edoxaban

Click here to­ read full press release/ article | Ref:Daiichi Sankyo | Image: Glassdoor

Vartika Singh

Vartika Singh is a content writer who loves to write research articles and reports at PharmaShots. She has in-depth knowledge of the life sciences industry including the Pharma and Biotech sectors. Any articles written by her can be contacted at connect@pharmashots.com.

Related post